Literature DB >> 30946639

Transcriptional CDKs in the spotlight.

Joaquin M Espinosa1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30946639      PMCID： PMC6602558          DOI： 10.1080/21541264.2019.1597479

Source DB:  PubMed          Journal:  Transcription        ISSN： 2154-1272


× No keyword cloud information.
  9 in total

Review 1.  Roles of CDKs in RNA polymerase II transcription of the HIV-1 genome.

Authors:  Andrew P Rice
Journal:  Transcription       Date:  2018-11-15

Review 2.  CDK9: a signaling hub for transcriptional control.

Authors:  Curtis W Bacon; Iván D'Orso
Journal:  Transcription       Date:  2018-10-11

Review 3.  Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.

Authors:  Arno L Greenleaf
Journal:  Transcription       Date:  2018-10-22

Review 4.  Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery.

Authors:  Robert P Fisher
Journal:  Transcription       Date:  2018-12-06

5.  The CDK Network: Linking Cycles of Cell Division and Gene Expression.

Authors:  Robert P Fisher
Journal:  Genes Cancer       Date:  2012-11

6.  Comparative genomics of cyclin-dependent kinases suggest co-evolution of the RNAP II C-terminal domain and CTD-directed CDKs.

Authors:  Zhenhua Guo; John W Stiller
Journal:  BMC Genomics       Date:  2004-09-20       Impact factor: 3.969

Review 7.  Cyclin-dependent kinases.

Authors:  Marcos Malumbres
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

Review 8.  Regulatory functions of the Mediator kinases CDK8 and CDK19.

Authors:  Charli B Fant; Dylan J Taatjes
Journal:  Transcription       Date:  2018-12-26

Review 9.  Therapeutic targeting of transcriptional cyclin-dependent kinases.

Authors:  Matthew D Galbraith; Heather Bender; Joaquín M Espinosa
Journal:  Transcription       Date:  2018-11-09
  9 in total
  2 in total

1.  Co-expression patterns explain how a basic transcriptional role for MYC modulates Wnt and MAPK pathways in colon and lung adenocarcinomas.

Authors:  Melanie Haas Kucherlapati
Journal:  Cell Cycle       Date:  2022-04-19       Impact factor: 5.173

2.  One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma.

Authors:  Guillermo Flores; Patrick J Grohar
Journal:  J Bone Oncol       Date:  2021-12-01       Impact factor: 4.072
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.